Publications by authors named "Miriam Droste"

Claim this Profile
T
Targeting CD276 with Adapter-CAR T-cells provides a novel therapeutic strategy in small cell lung cancer and prevents CD276-dependent fratricide.
Beate Kristmann, Niels Werchau, Lakshmi Suresh, Elisabeth L Pezzuto, Sophia Scheuermann, Miriam Droste

J Hematol Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and Characterization of Fully Human FOLR1-Targeting CAR T Cells for the Treatment of Ovarian Cancer.
Maria Bethke, Pierre Abramowski, Miriam Droste, André Felsberger, Lisa Kochsiek

Cells· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation of Endotoxin-Specific Monoclonal Antibodies by Phage and Yeast Display for Capturing Endotoxin.
Alexandra C Fux, Cristiane Casonato Melo, Laura Schlahsa, Nico B Burzan, André Felsberger, Miriam Droste

Int J Mol Sci· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A switchable secrete-and-capture system enables efficient selection of Pichia pastoris clones producing high yields of Fab fragments.
Dominic Gätjen, Marek Wieczorek, Martin Listek, Florian Tomszak, Volker Nölle, Miriam Droste

J Immunol Methods· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a novel switchable antibody display system in Pichia pastoris.
Dominic Gätjen, Florian Tomszak, Johann-Christoph Dettmann, Miriam Droste, Volker Nölle

Appl Microbiol Biotechnol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling.
Elisa Landoni, Giovanni Fucá, Jian Wang, Venkat R Chirasani, Zhiyuan Yao, Miriam Droste

Cancer Immunol Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma.
Anthony B Eason, Sang-Hoon Sin, Mohsin Shah, Hong Yuan, Douglas J Phillips, Miriam Droste

PLoS One· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models.
Emese Szabó, Douglas J Phillips, Miriam Droste, Andrea Marti, Titus Kretzschmar

J Pharmacol Exp Ther· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noninvasive measurement of cell volume changes by negative staining.
Miriam S Droste, Stefan S Biel, Lara Terstegen, Klaus-Peter Wittern, Horst Wenck

J Biomed Opt· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis